United States Artemisinin Combination Therapy Market is expected to reach US$ 1,061 million by 2031 | Major key players - Novartis AG, Ajanta Pharma, Schwitz Biotech.

Market Size and Growth:

The Global Artemisinin Combination Therapy Market size reached US$ 547 million in 2023 and is expected to reach US$ 1,061 million by 2031, growing at a CAGR of 8.8% during the forecast period 2024-2031. The Market is driven by the rising prevalence of malaria in tropical regions and increasing adoption of effective combination therapies for drug-resistant strains. According to DataM Intelligence

To Download a Free Sample PDF (Use Corporate email ID to Get Higher Priority) at: https://datamintelligence.com/download-sample/artemisinin-combination-therapy-market?sz

The Artemisinin Combination Therapy (ACT) Market refers to the global industry focused on the production, distribution, and commercialization of antimalarial drugs that combine artemisinin derivatives with partner medicines to enhance efficacy and reduce drug resistance. This market addresses growing malaria prevalence, especially in tropical regions, and supports global malaria elimination initiatives through effective treatment solutions.

Industry Recent Developments: United States

✅ October 2025: The U.S. actively continues to focus on research into new combination therapies to combat drug resistance, with ongoing development efforts and clinical trials aimed at improving existing ACT formulations.

✅ August 2025: There has been an increase in government initiatives to support malaria eradication programs, emphasizing the need for affordable and effective ACT drugs in the U.S. health system.

✅ July 2025: The U.S. pharmaceutical industry is investing in innovative ACT formulations, focusing on reducing side effects and improving compliance among diverse patient groups.

Industry Recent Developments: Japan

✅ October 2025: Japan is preparing to expand its market share by investing in the development of new ACT formulations, targeting both domestic and Southeast Asian markets.

✅ September 2025: The Japanese government has approved increased funding for malaria treatment research, including the development of resistant-strain combatting ACTs.

✅ July 2025: Japan's market is projected to grow, with increasing imports of ACT drugs to meet rising demand driven by malaria cases in tourism and expatriate communities.

Get Customization in the report as per your requirements + Exclusive Bundle & Multi-User Discounts: https://datamintelligence.com/customize/artemisinin-combination-therapy-market?sz

Regulatory Approvals / policy updates in 2025:

✅ Swissmedic approved a new infant formulation of Coartem - "Coartem Baby" (artemether-lumefantrine) - on 8 July 2025. This formulation is the first malaria medicine specifically licensed for newborns and very young infants (under ~4.5 kg). Novartis and MMV developed it to close the treatment gap for the smallest patients.

✅ Eight African countries participated in the Swissmedic assessment and were expected to fast-track national approvals under the Swiss "Marketing Authorization for Global Health Products" route - these countries were reported as Burkina Faso, Côte d'Ivoire, Kenya, Malawi, Mozambique, Nigeria, Tanzania, and Uganda (rollout in Africa expected during 2025).

✅ WHO malaria guidance (updated/issued in 2025) continued to emphasise ACTs as first-line therapies, recommended close monitoring of drug efficacy and resistance, and encouraged national regulatory authorities to ensure quality and availability of antimalarials. (WHO guidance published August 13, 2025).

Mergers & Acquisitions:

✅ Direct ACT-specific M&A activity in 2025 was limited - there were no widely reported, major acquisitions focused solely on ACT product lines during 2025. Market commentary and sector reports note relatively modest, targeted M&A in antimalarial segments (most activity remains partnership / R&D focused rather than headline acquisitions).

✅ Large pharma deals that can indirectly affect ACT supply & strategy: Novartis - a major ACT supplier - was an active acquirer in 2025 (multiple big deals announced during the year), including a high-profile acquisition announced in October 2025. While these deals are not ACT-product purchases, Novartis' scale and spending can influence manufacturing capacity, global health priorities, and distribution strategies for products such as Coartem.

✅ Partnerships / public-private collaborations remained important: the Novartis + MMV (Medicines for Malaria Venture) collaboration that developed Coartem Baby is the leading 2025 example of a development/rollout partnership aimed directly at improving ACT access for infants. Such partnerships - rather than large M&A - were the main commercial dynamic driving new ACT formulations and country rollouts in 2025.

Major Key Players:

Novartis AG
Ajanta Pharma
Shinpoong Pharm.co., Ltd
Schwitz Biotech
Stravahealthcare
Enzymes Pharmaceuticals
Wellona Pharma
Saphnix Life Sciences
Centurion Laboratories Private Limited
SiNi Pharma Pvt Ltd.

Segments Covered in the Artemisinin Combination Therapy Market:

By Combination Therapy Type: Artemether-Lumefantrine, Artesunate-Amodiaquine, Artesunate-Pyronaridine, Artesunate-Sulfadoxine-Pyrimethamine, Others.

By End-User: Hospital, Clinics, Research Centers, Others.

Regional Analysis for Artemisinin Combination Therapy Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=artemisinin-combination-therapy-market

Chapter Outline:

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Artemisinin Combination Therapy market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Artemisinin Combination Therapy Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The global Artemisinin Combination Therapy market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Artemisinin Combination Therapy Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Frequently asked questions:

➠ What is the global sales value, production value, consumption value, import and export of Artemisinin Combination Therapy market?

➠ Who are the global key manufacturers of the Artemisinin Combination Therapy Industry? How is their operating situation (capacity, production, sales, price, cost, gross, and revenue)?

➠ What are the Artemisinin Combination Therapy market opportunities and threats faced by the vendors in the global Artemisinin Combination Therapy Industry?

➠ Which application/end-user or product type may seek incremental growth prospects? What is the market share of each type and application?

➠ What focused approach and constraints are holding the Artemisinin Combination Therapy market?

➠ What are the different sales, marketing, and distribution channels in the global industry?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.